# Mubadala Capital Ventures

> Mubadala Capital Ventures is a VC fund backing Biotechnology and Health Care. See 129 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 129
- Last investment: Jun 2026
- Lead investor: 26%
- Last fund: Oct 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mubadala/
- X (Twitter): https://twitter.com/Mubadala
- Website: https://www.mubadala.com/
- Facebook: https://www.facebook.com/Mubadala

Mubadala Capital Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Mubadala Capital’s Ventures business builds on Mubadala’s 10-year track record of being an active investor in advanced technology. The Ventures platform includes a direct investment business, a fund of funds business and the management and oversight of Mubadala’s partnership with SoftBank, including its U.S. $15 billion LP commitment to theSoftBank Vision Fund. The Ventures team is based in Abu Dhabi, San Francisco, and London with strong connectivity to European and Chinese venture capital markets through other Mubadala Capital managed vehicles.

## Contacts

5 contacts available for Mubadala Capital Ventures. Shizune tracks 7 team members at Mubadala Capital Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mubadala-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 22 | 17% |
| Health Care | 21 | 16% |
| Software | 15 | 12% |
| Therapeutics | 12 | 9% |
| Medical | 9 | 7% |

114 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 27 | 21% |
| Series B | 27 | 21% |
| Series C | 12 | 9% |
| Series D | 9 | 7% |
| Seed | 8 | 6% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 54 | 42% |
| United Kingdom | 5 | 4% |
| Germany | 4 | 3% |
| Sweden | 2 | 2% |
| Russian Federation | 2 | 2% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ibrahim Ajami | Head of Mubadala Ventures | 19 | https://shizune.co/investors/profile/ibrahim-ajami |
| Abdulla AlBanna | Partner | 2 | https://shizune.co/investors/profile/abdulla-albanna |
| Alasdair Thong | Venture Partner | 8 | https://shizune.co/investors/profile/alasdair-thong |
| Chetna Goyal | Investment Professional | 0 | https://shizune.co/investors/profile/chetna-goyal |
| Khaled Abdulla Al Qubaisi | Chief Human Group Capital Officer | 6 | https://shizune.co/investors/profile/khaled-abdulla-al-qubaisi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Greenlink | Greenlink, a joint venture between Baltic Cable and Equitix, runs a 504MW underwater electrical interconnector that connects Ireland and Great Britain. | $200M | Private Equity | Jun 16, 2026 |  |
| KOHO Financial | KOHO Financial provides an application based banking platform intended to simplify financial products available to everyone. Its platform helps users to complete their day to day banking operations while offering tools such as goals, cash flow projections, group spending, spending insights, and categorizations, enabling users to manage theirexpenses and banking operations on the go. | $93.2M | Series E | Jun 10, 2026 |  |
| Alloy Therapeutics | Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts. | $40M | Series E | Apr 15, 2026 |  |
| Tahoe Therapeutics | Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $30M | Series A | Aug 11, 2025 |  |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M | Series B | Feb 04, 2025 |  |
| Firstvet | FirstVet is a video consultation platform that connects veterinarians, directly on the user's smartphone, tablet, or computer.The app aims to care about a pet and offers help and advice. It helps users to determine when they need to seek care for a pet suffering from stomach problems. They provide consultation, medicinal prescriptions, andrelated services through both mobile applications and their website. Founded in 2016, the company is headquartered in Stockholm, Stockholms Lan, Sweden by David Prien and Joakim Widigs. | $21.5M | Series C | Jun 24, 2024 |  |
| Storyblok | Storyblok says its CMS provides ‘highly customizable content blocks and visual editing tools’ in n contrast to other headless CMS solutions which are flexible for developers but might be less so for actual editors to edit. | $80.1M | Series C | Jun 04, 2024 |  |
| Storyblok | Storyblok says its CMS provides ‘highly customizable content blocks and visual editing tools’ in n contrast to other headless CMS solutions which are flexible for developers but might be less so for actual editors to edit. | $80.1M | Series C | Jun 04, 2024 |  |
| Arbol | Arbol is launching an insurance marketplace that connects weather exposed agricultural entities with capital providers like insurers and asset managers. Arbol’s parametric insurance platform removes information asymmetry and reduces administrative costs by leveraging objective data from satellites and weather stations. | $60M | Series B | Apr 30, 2024 |  |
| Metsera | Metsera operates as a clinical-stage biopharmaceutical company. | $290M | Series A | Apr 18, 2024 |  |

10 of 129 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 18 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 14 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 9 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 9 deals together
- [WestCap](https://shizune.co/investors/profile/westcap-sf) — VC Fund, 9 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 8 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Mubadala Capital Ventures invest in?

Mubadala Capital Ventures invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 129 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mubadala Capital Ventures?

Public channels for Mubadala Capital Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mubadala Capital Ventures?

The team at Mubadala Capital Ventures includes Ibrahim Ajami (Head of Mubadala Ventures), Abdulla AlBanna (Partner) and Alasdair Thong (Venture Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co